Steroid-resistant sarcoidosis: Is antagonism of TNF-α the answer?

Clinical Science

Volumn 112, Issue 5-6, 2007, Pages 281-289

  Denys, Bart G ^a   Bogaerts, Yves ^a   Coenegrachts, Kenneth L ^a   De Vriese, An S ^a  

^a AZ Sint Jan AV ^*  (Belgium)

Author keywords

Alveolar macrophage; Inflammation; Respiratory tract; Sarcoidosis; Steroid resistance; Tumour necrosis factor (TNF )

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PENTOXIFYLLINE; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALOPECIA; ASEPTIC MENINGITIS; BLADDER CARCINOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESISTANCE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEMORRHAGIC CYSTITIS; HEPATITIS; HIRSUTISM; HUMAN; HYPERTENSION; HYPOTENSION; HYPOTHYROIDISM; IMMUNOBLASTIC LYMPHOMA; IMMUNOSUPPRESSIVE TREATMENT; INFERTILITY; LEUKOPENIA; LIVER FIBROSIS; LIVER TOXICITY; NAUSEA; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RASH; REVIEW; SARCOIDOSIS; STOMATITIS; TERATOGENICITY; THRUSH; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; TUBERCULOSIS; VASCULITIS;

ANTIBODIES, MONOCLONAL; BIOLOGICAL RESPONSE MODIFIERS; DRUG RESISTANCE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; OPPORTUNISTIC INFECTIONS; RECEPTORS, TUMOR NECROSIS FACTOR; SARCOIDOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33847787156     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20060094     Document Type: Review

References (75)

1. Baughman, R. P. (2004) Pulmonary sarcoidosis. Clin. Chest Med. 25, 521-530
2. Wu, J. J. and Schiff, K. R. (2004) Sarcoidosis. Am. Fam. Physician 70, 312-322
3. Paramothayan, S. and Jones, P. W. (2002) Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA, J. Am. Med. Assoc. 287, 1301-1307
4. Baughman, R. P. and Lower, E. E. (1999) A clinical approach to the use of methotrexate for sarcoidosis. Thorax 54, 742-746
5. ATS Guidelines on Sarcoidosis (1999) Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am. J. Respir. Crit. Care Med. 160, 736-755
6. Lower, E. E. and Baughman, R. P. (1995) Prolonged use of methotrexate for sarcoidosis. Arch. Intern. Med. 155, 846-851
7. Agbogu, B. N., Stern, B. J., Sewell, C. and Yang, G. (1995) Therapeutic considerations in patients with refractory neurosarcoidosis. Arch. Neurol. 52, 875-879
8. Demeter, S. L. (1988) Myocardial sarcoidosis unresponsive to steroids. Treatment with cyclophosphamide. Chest 94, 202-203
9. Bielory, L. and Frohman, L. P. (1991) Low dose cyclosporine therapy of granulomatous optic neuropathy and orbitopathy. Ophtalmology 98, 1732
10. Kavanaugh, A. F., Andrew, S. L., Cooper, B., Lawrence, E. C. and Huston, D. P. (1987) Cyclosporine therapy of central nervous system sarcoidosis. Am. J. Med. 82, 387
11. O'Callaghan, C. A., Wells, A. U., Lalvani, A., Dhillon, P. D., Hansell, D. M. and Mitchell, D. N. (1994) Effective use of cyclosporin in sarcoidosis: a treatment strategy based on computed tomography scanning. Eur. Respir. J. 7, 2255-2256
12. Wyser, C. P., van Schalkwyk, E. M., Alheit, B., Bardin, P. G. and Joubert, J. R. (1997) Treatment of progressive pulmonary sarcoidosis with cyclosporin A. Am. J. Respir. Crit. Care Med. 156, 1371-1376
13. Baltzan, M., Mehta, S., Kerkham, T. H. and Cosio, M. G. (1999) Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 160, 192-197
14. Johns, C. J., Zachary, J. B., MacGregor, M. I., Curtis, J. L., Scott, P. P. and Terry, P. B. (1982) The longitudinal study of chronic sarcoidosis. Trans Am. Clin. Climatol. Assoc. 82, 173
15. Zic, J. A., Horowitz, D. H., Arzubiaga, C. and King, Jr, T. E. (1991) Treatment of cutaneous sarcoidosis with chloroquine. Review of the literature. Arch. Dermatol. 12, 1034-1040
16. Hilton, J. M., Cooper, D. M. and Henry, R. L. (1997) Hydroxychloroquine therapy of diffuse pulmonary sarcoidosis in two Australian male children. Respirology 2, 71-74
17. Baughman, R. P., Judson, M. A., Teirstein, A. S., Moller, D. R. and Lower, E. E. (2002) Thalidomide for chronic sarcoidosis. Chest 122, 227-232
18. Marques, L. J., Zheng, L., Poulakis, N., Guzman, J. and Costabel, U. (1999) Pentoxifylline inhibits TNF-α production from human alveolar macrophages. Am. J. Respir. Crit. Care Med. 159, 508-511
19. Zabel, P., Entzian, P., Dalhoff, K. and Schlaak, M. (1997) Pentoxifylline in treatment of sarcoidosis. Am. J. Respir. Crit. Care Med. 155, 1665-1669
20. Nunes, H., Soler, P. and Valeyre, D. (2005) Pulmonary sarcoidosis. Allergy 60, 565-582
21. Baughman, R. P., Stohofer, S. A., Buchsbaum, J. and Lower, E. E. (1990) Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J. Lab. Clin. Med. 115, 36-42
22. Ziegenhagen, M. W., Benner, U. K., Zissel, G., Zabel, P., Schlaak, M. and Muller-Quernheim, J. (1997) Sarcoidosis: TNF-α release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am. J. Respir. Crit. Care Med. 156, 1586-1592
23. Fehrenbach, H., Zissel, G., Goldmann, T. et al. (2003) Alveolar macrophages are the main source for tumour necrosis factor-α in patients with sarcoidosis. Eur. Respir. J. 21, 421-428
24. Bazzoni, F. and Beutler, B. (1996) The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 334, 1717-1725
25. Dai, H., Guzman, J., Chen, B. and Costabel, U. (2005) Production of soluble tumor necrosis factor receptors and tumor necrosis factor-α by alveolar macrophages in sarcoidosis and extrinsic allergic alveolitis. Chest 127, 251-256
26. Russo, C. and Polosa, R. (2005) TNF-α as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis. Clin. Sci. 109, 135-142
27. Masahiro, S., Yuriko, N., Takefumi, I. et al. (2001) Role of ICAM-1 in the aggregation and adhesion of human alveolar macrophages in response to TNF-α and INF-γ. Mediators Inflammation 10, 309-313
28. Garcia, I., Miyazaki, Y., Marchal, G., Lesslauer, W. and Vassalli, P. (1997) High sensitivity of transgenic mice expressing soluble TNFR1 fusion protein to mycobacterial infections: synergistic action of TNF and IFN-γ in the differentiation of protective granulomas. Eur. J. Immunol. 27, 3182-3190
29. Seitzer, U., Swider, C., Stüber, F. et al. (1997) Tumour necrosis factor α promotor gene polymorphism in sarcoidosis. Cytokine 9, 787-790
30. Takashege, N., Naruse, T. K., Matsumori, A. et al. (1999) Genetic polymorphisms at the tumour necrosis factor loci (TNFA and TNFB) in cardiac sarcoidosis. Tissue Antigens 54, 191-193
31. Somoskövi, A., Zissel, G., Seitzer, U., Gerdes, J., Schlaak, M. and Müller-Quernheim, J. (1999) Polymorphisms at position -308 in the promoter region of the TNF-α and in the first intron of the TNF-β genes and spontaneous and lipopolysaccharide-induced TNF-α release in sarcoidosis. Cytokine 11, 882-887
32. Grutters, J. C., Sato, H., Pantelidis, P. et al. (2002) Increased frequency of the uncommon tumor necrosis factor -857T allele in British and Dutch patients with sarcoidosis. Am. J. Respir. Crit. Care Med. 165, 1119-1124
33. Müller-Quernheim, J., Kienast, K., Held, M., Pfeifer, S. and Costabel, U. (1999) Treatment of chronic sarcoidosis with an azathioprine/prednisone regimen. Eur. Respir. J. 14, 1117-1122
34. Baughman, R. P. and Lower, E. E. (1990) The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am. Rev. Respir. Dis. 142, 1268-1271
35. Tong, Z., Dai, H., Chen, B., Abdoh, Z., Guzman, J. and Costabel, U. (2003) Inhibition of Cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline. Chest 124, 1526-1532
36. Tavares, J. L., Wangoo, A., Dilworth, P., Marshall, B., Kotecha, S. and Shaw, R. J. (1997) Thalidomide reduces tumour necrosis factor-α production by human alveolar macrophages. Respir. Med. 91, 31-39
37. Jang, C. H., Choi, J. H., Byun, M. S. and Jue, D. M. (2006) Chloroquine inhibits production of TNF-α, IL-1β and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology 45, 703-710
38. Baughman, R. P. and Iannuzzi, M. (2003) Tumour necrosis factor in sarcoidosis and its potential for targeted therapy. BioDrugs 17, 425-431
39. Katz, J. M., Bruno, M. K., Winterkorn, J. M. and Nealon, N. (2003) The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab. Arch. Neurol. 60, 426-430
40. Pettersen, J. A., Zochodne, D. W., Bell, R. B., Martin, L. and Hill, M. D. (2002) Refractory neurosarcoidosis responding to infliximab. Neurology 59, 1660-1661
41. Meyerle, J. H. and Shorr, A. (2003) The use of infliximab in cutaneous sarcoidosis. J. Drugs Dermatol. 2, 413-114
42. Mallbris, L., Ljungberg, A. and Hedblad, M. A. (2003) Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-α therapy. J. Am. Acad. Dermatol. 48, 290-293
43. Haley, H., Cantrell, W. and Smith, K. (2004) Infliximab therapy for sarcoidosis (lupus pernio). Br. J. Dermatol. 150, 146-149
44. Menon, Y., Cucurull, E., Reisin, E. and Espinoza, L. R. (2004) Interferon-α-associated sarcoidosis responsive to infliximab therapy. Am. J. Med. Sci. 328, 173-175
45. Fouchier, S. M., Moller, G. M., Van Santen, H. M. et al. (2004) Successful treatment with infliximab of a patient with refractory sarcoidosis. Ned. Tijdschr. Geneeskd. 148, 2446-2450
46. Ulbricht, K. U., Stoll, M., Bierwirth, J., Witte, T. and Schmidt, R. E. (2003) Successful tumor necrosis factor α blockade treatment in therapy resistant sarcoidosis. Arthritis Rheum. 48, 3542-3543
47. Roberts, S. D., Wilkes, D. S., Burgett, R. A. and Knox, K. S. (2003) Refractory sarcoidosis responding to infliximab. Chest 124, 2028-2031
48. Yee, A. M. and Pochapin, M. B. (2001) Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-α therapy. Ann. Intern. Med. 135, 27-31
49. Baughman, R. P. and Lower, E. E. (2001) Infliximab for refractory sarcoidosis. Sarcoidosis Vase. Diffuse Lung Dis. 18, 310
50. Pritchard, C. and Nadarajah, K. (2004) Tumour necrosis factor α inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann. Rheum. Dis. 64, 318-320
51. Doty, J. D., Mazur, J. E. and Judson, M. A. (2005) Treatment of sarcoidosis with infliximab. Chest 127, 1064-1071
52. Baughman, R. P., Drent, M., Kavuru, M. et al. (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am. J. Resp. Grit. Care Med. 174, 795-802
53. Khanna, D., Liebling, M. and Louie, J. S. (2003) Etanercept ameliorates sarcoidosis arthritis and skin disease. J. Rheumatol. 30, 1864-1867
54. Baughman, R. P., Lower, E. E., Bradley, D. A., Raymond, L. A. and Kaufman, A. (2005) Etanercept for refractory ocular sarcoidosis. Chest 128, 1062-1067
55. Utz, J. P., Limper, A. H., Kalra, S. et al. (2003) Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 124, 177-185
56. Philips, M. A., Lynch, J. and Azmi, F. H. (2005) Ulcerative cutaneous sarcoidosis responding to adalimumab. J. Am. Acad. Dermatol. 53, 917
57. Callejas-Rubio, J. L., Ortego-Centeno, N., Lopez-Perez, L. and Benticuaga, M. N. (2006) Treatment of therapy-resistant sarcoidosis with adalimumab. Clin. Rheumatol. 25, 596-597
58. Keane, J., Gershon, S., Wise, R. P. et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med. 345, 1098-1104
59. Efde, M. N., Houtman, P. M., Spoorenberg, J. P. and Jansen, T. L. (2005) Tonsillar tuberculosis in a rheumatoid arthritis patient receiving anti-TNFα (adalimumab) treatment. Neth. J. Med. 63, 112-114
60. Slifman, N. R., Gershon, S. K., Lee, J. H., Edwards, E. T. and Braun, M. M. (2003) Listena monocytogenes infection as a complication of treatment with tumor necrosis factor α-neutralizing agents. Arthritis Rheum. 48, 319-324
61. Keystone, E. C. (2005) Safety of biologic therapies: an update. J. Rheumatol. 32 (Suppl. 74), 8-12
62. Wood, K. L., Hage, C. A., Knox, K. S. et al. (2003) Histoplasmosis after treatment with anti-tumor necrosis factor-α therapy. Am. J. Respir. Crit. Care Med. 167, 1279-1282
63. Kneitz, C., Suerbaum, S., Beer, M., Muller, J., Jahns, R. and Tony, H. P. (2005) Exacerbation of Whipple's disease associated with infliximab treatment. Scand. J. Rheumatol. 34, 148-151
64. Mohan, N., Edwards, E. T., Cupps, T. R. et al. (2004) Leucocytoclastic vasculitis associated with tumor necrosis factor-α blocking agents. J. Rheumatol. 31, 1885-1887
65. Krishnan, R. S. and Hsu, S. (2004) Serum sickness due to infliximab in a patient with psoriasis. J. Drugs Dermatol. 3, 305-308
66. Ferraro, C., Coury, F., Tebib, J. G., Bienvenu, J. and Fabien, N. (2004) Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphopholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res. Ther. 6, R535-R543
67. De Bandt, M., Sibilia, J., Le Loet, X. et al. (2005) Systemic lupus erythematosus induced by anti-tumour necrosis factor α therapy: a French national survey. Arthritis Res. Ther. 7, R545-R551
68. Shakoor, N., Michalska, M., Harris, C. A. and Block, J. A. (2002) Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359, 579-580
69. Riegert, D. L., Godfrey, J. A., Myers, J. L., Hubmayr, R. D., Sandborn, W. J. and Loftus, Jr, E. V. (2002) Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm. Bowel Dis. 8, 186-191
70. Marotte, H., Charrin, J. E. and Miossec, P. (2001) Infliximab-induced aseptic meningitis. Lancet 358, 1252
71. Favalli, E. G., Varenna, M. and Sinigaglia, L. (2005) Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy. Clin. Exp. Rheumatol. 23, 247-250
72. Kwon, H. J., Cote, T. R., Cuffe, M. S., Kramer, J. M. and Braun, M. M. (2003) Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med. 138, 807-811
73. Thurber, M., Feasel, A., Stroehlein, J. and Hymes, S. R. (2004) Pustular psoariasis induced by infliximab. J. Drugs Dermatol. 3, 439-440
74. Verea, M. M., Del Pozo, J., Yebra-Pimentel, M. T., Porta, A. and Fonseca, E. (2004) Psoriasiform eruption induced by infliximab. Ann. Pharmacother. 38, 54-57
75. Koenig, M., Cathebras, P., Guy, C. and Rousset, H. (2006) Pentoxifylline: a cheap substitute for anti-TNFα agents? Rev. Med. Interne 27, 400-405